IGC Pharma
3 hedge funds and large institutions have $4K invested in IGC Pharma in 2016 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 5 closing their positions.
63% less funds holding
Funds holding: 8 → 3 (-5)
97% less capital invested
Capital invested by funds: $147K → $4K (-$143K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Creative Planning
Overland Park,
Kansas
|
+$481 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$87K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$28K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$15K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$7K |
IGC Hedge Fund Activity: Q2 2016 in Review
3 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q2 2016, worth a combined $4K — down 97% from $147K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IGC and 0 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Creative Planning, adding an estimated $481. The largest seller was Citadel Advisors, exiting entirely with an estimated $87K sold.
- 3 institutional investors held IGC Pharma (IGC) as of Q2 2016, down from 8 in Q1 2016.
- Funds reported $4K of IGC Pharma stock for Q2 2016, down 97% quarter-over-quarter.
- 0 funds opened new IGC Pharma positions in Q2 2016 and 5 closed out, a net change of -5 holders.
- The largest IGC Pharma buyer in Q2 2016 was Creative Planning, an estimated $481 added.
- The largest IGC Pharma seller in Q2 2016 was Citadel Advisors, an estimated $87K sold.
Based on aggregated 13F filings for Q2 2016.